Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.
| Revenue (Most Recent Fiscal Year) | $5.82M |
| Net Income (Most Recent Fiscal Year) | $71.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.87 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 1224.79% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -60.65% |
| Return on Assets (Trailing 12 Months) | -40.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.74 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | 0.47 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.34 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.03 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.05M |
| Free Float | 53.97M |
| Market Capitalization | $313.77M |
| Average Volume (Last 20 Days) | 1.14M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |